Boundless Bio, Inc. — Director's Dealing 2024

Mar 28, 2024

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Boundless Bio, Inc. (BOLD)
CIK: 0001782303
Period of Report: 2024-03-27

Reporting Person: RA CAPITAL MANAGEMENT, L.P. (N/A)
Reporting Person: RA Capital Healthcare Fund LP (10% Owner)
Reporting Person: RA Capital Nexus Fund II, L.P. (10% Owner)
Reporting Person: Kolchinsky Peter (10% Owner)
Reporting Person: Shah Rajeev M. (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock	$		Common Stock (871794)		Indirect
Series B Preferred Stock	$		Common Stock (153846)		Indirect
Series C Preferred Stock	$		Common Stock (716118)		Indirect
Series C Preferred Stock	$		Common Stock (126373)		Indirect

Footnotes

F1: Each share of Series B Preferred Stock and Series C Preferred Stock will automatically convert into shares of Common Stock on a 19.5-for-1 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F2: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F4: Held directly by Nexus Fund II.